#USA #Orlando #UCB #Psoriasis #BIMZELX

Sustained Efficacy of BIMZELX® in Moderate-to-Severe Plaque Psoriasis

The recent findings from the AAD 2025 conference reveal promising results for patients suffering from moderate-to-severe plaque psoriasis treated with BIMZELX® (bimekizumab-bkzx). The data presented by UCB, a biopharmaceutical leader, show remarkable sustained skin clearance over a five-year period, underscoring the long-term benefits of this innovative treatment.

In a detailed study involving 153 patients from the BE BRIGHT extension trials, a significant 67.7% achieved complete skin clearance, denoted as PASI100. This is a testament to the effectiveness of BIMZELX® in tackling chronic plaque psoriasis. In addition, a noteworthy 84.9% of these patients recorded a PASI90, indicating extensive improvements in their skin condition over the same period.

Dr. Andrew Blauvelt, Chair of the Medical Board at the National Psoriasis Foundation, emphasized the importance of these results, stating, "For individuals living with psoriasis, achieving and maintaining clear skin is crucial for improving quality of life. The five-year data from BIMZELX® provide essential insights into effective long-term management strategies for this chronic condition."

Dual Inhibition Mechanism

BIMZELX® stands out as the first and only authorized medication designed to dual-inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F). This dual-action approach enhances its efficacy in treating inflammatory processes in psoriasis. Clinical trials indicate that this mechanism not only aids in achieving clear skin but also reduces the risk of related health complications associated with psoriasis, such as psoriatic arthritis (PsA).

Data show that over three years, 68.7% to 71.6% of patients at risk for developing PsA achieved complete skin clearance, aligning closely with the overall results for all treated psoriasis patients. This suggests that even those at higher risk can experience substantial benefits from BIMZELX® treatment.

Long-Term Safety and Tolerability

In terms of safety, BIMZELX® was found to be well tolerated among participants, with adverse events similar to those observed in prior studies. Common treatment-emergent adverse events included upper respiratory infections and oral candidiasis, which reinforces an encouraging safety profile as well as long-term adherence viability for patients. UCB reported no unexpected safety findings during the five-year period.

Fiona du Monceau, Executive Vice President of UCB, highlighted the transformative potential of BIMZELX® for psoriasis patients, noting that long-term skin clearance can significantly improve overall health outcomes. "People living with psoriasis often face increased risks of serious health issues—these five-year results could mark a turning point for better health management strategies in this patient population."

Moreover, UCB is committed to advancing the understanding of BIMZELX®'s effectiveness across various immune-mediated inflammatory diseases, as evidenced by their presentations at the AAD, which included data on conditions like hidradenitis suppurativa and PsA.

Conclusion

With the findings from AAD 2025, BIMZELX® emerges as a frontrunner in the long-term management of moderate-to-severe plaque psoriasis. Its sustained efficacy and safety profile may redefine treatment strategies, offering patients a renewed hope for lasting skin health. As UCB continues its research initiatives, the commitment to enhancing the lives of individuals affected by inflammatory diseases remains at the forefront of their mission.